Skip to main content
. 2018 Dec 12;9:2941. doi: 10.3389/fimmu.2018.02941

Figure 1.

Figure 1

The figure describes the critical mechanisms involved in three phases of the immune-response against cancer and available drugs and strategies which may improve its efficacy Upper row: Specific cell lineages, molecular structures and immune-checkpoints involved in immunopriming process (A), T cell Homing (B), and modulation of CTL mediated Tumor cell killing (C). Bottom row: Strategies (AKA radiation therapy), cytotoxic Drugs, cytokines and Immunocheckpoint inhibitors interfering with the immunopriming (A), T cell Homing (B), and T cell mediated killing (C). APCs, antigen presenting cells; CTL-TCR, cytotoxic T lymphocites–T cell Receptor; HLA, Human Leucocyte Antigen; MDSCs, myeloid derived suppressor cells; TAA, Tumor Associated Antigen; TSA, Tumor Specific Antigen; ICD, Immunogenic Cell Death inducers; GM-CSF, Granulocyte-macrophage colony-stimulating factor; IFNs, interferons; ASI, active specific immunotherapy; TKI, tyrosine kinase inhibitor; CTLA-4, Cytotoxic T cell antigen−4; PD-1, Programmed cell death receptor-1; PDL, Programmed cell death ligand.